There main defence is that MEPACT is a speculative play at best
“The projections did not include any estimates of the financial performance or expenses for MEPACT in the U.S. due to the substantial risks and uncertainties related to when, if ever, the Company might receive FDA approval for MEPACT. Additionally, and likely because of these substantial risks and uncertainties, the Company was informed by each of Takeda, Company B and Company A discussed above under “—Background of the Offer” that their final bids for the Company did not place any value on the U.S. market for MEPACT.”
Bow you hit it on the head, these guys are getting a steal of a deal but in this market I guess thats how the ball bounces these days. The numbers definitely show there is more than 2.64 worth of potential here BUT its obviously apparent they didn't turn down any offers for 5.00 a share from anyone else. Like my friends email stated, this gave us almost a dollar over close before the deal and the BOD gets all their bonuses.
D
Market Data 
Markets 
AI
